Rapport Therapeutics, Inc. has announced a significant stock acquisition by its director, Paul Steven M. On October 22, 2026, he acquired 35,714 shares at a price of $27.28 each. This transaction is noteworthy as it demonstrates the director's confidence in the company's future prospects.
Rapport Therapeutics, Inc., classified under the SIC code 2834 for Pharmaceutical Preparations, operates as an emerging growth company. The firm is listed on the Nasdaq under the ticker symbol RAPP. The company is headquartered in Boston, Massachusetts, and has been active in filing various reports with the SEC, including recent transactions and financial disclosures.
The recent filing indicates that Paul Steven M, a director of Rapport Therapeutics, acquired the shares through Paul Capital Strategy III Fund LLC. Following this transaction, he now holds a total of 77,380 shares in the company. The filing notes that the shares were purchased at a weighted average price, with individual transactions ranging from $26.87 to $27.84. The filing states, "The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected."
This acquisition may affect investor sentiment and could lead to increased scrutiny on the company's future performance. As the pharmaceutical preparations industry continues to evolve, such strategic moves by directors can influence market perceptions and investor confidence.
The filing does not say what happens next.